Previous 10 | Next 10 |
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire ANDOVER, Mass. , July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ t...
TransMedics Group (TMDX) announces that after review and discussion of its clinical evidence from the OCS Liver PROTECT trial, the FDA Advisory Committee has issued a favorable vote in support of approval of the OCS Liver System. The panel voted 14 to 0, that there is reasonable assurance tha...
TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System Panel votes unanimously in support of the OCS Liver System's safety and effectiveness PR Newswire ANDOVER, Mass. , July 14, 2021 /PRNewswire/ -- TransMedics Group...
The Nasdaq has halted trading of TransMedics Group's (TMDX) common stock ahead of FDA meeting to review the company's Premarket Approval Application for Organ Care System ((OCS)) Liver System.The Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will meet to...
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System PR Newswire ANDOVER, Mass. , July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medi...
TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting PR Newswire ANDOVER, Mass. , June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021) PR Newswire ANDOVER, Mass. , June 8, 2021 /PRNewswire...
David Abrams’ 13F portfolio value increased ~25% this quarter from $3.55B to $4.44B. The number of positions decreased from 17 to 16. Abrams Capital Management added Change Healthcare while dropping TransMedics Group during the quarter. The top three positions are Lithia Mo...
Gainers: [[CHMA]] +5.7%. [[STIM]] +5.2%. [[TMDX]] +3.3%. [[SELB]] +3.2%. [[CGEN]] +2.8%.Losers: [[WMG]] -12.8%. [[QMCO]] -4.8%. [[OKTA]] -4.2%. [[NXGN]] -3.9%. [[LIZI]] -3.8%. For further details see: CHMA, STIM, WMG and NXGN among after-hours movers
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiat...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...